Últimas noticias sobre GeneDx Holdings (NASDAQ:WGS) Bolsa

GeneDx Hldgs

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

LFCR

SPSC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: WGS, LFCR, SPSC, RGP y UDR.

5 acciones en el foco este viernes: WGS, LFCR, SPSC, RGP y UDR

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings Corp

Barclays analyst Ramsey El-Assal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Overweight and lowers the price target from $290 to $270.

Price Target

Analyst Ratings

EPAM

Barclays Maintains Overweight on EPAM Systems, Lowers Price Target to $270

On Monday, Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in <a href="http://Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains" target="_blank" rel="noreferrer noopener">vivo base editing</a>.
The initial safety and efficacy data reported are from all nine patients as of February 26, the data <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214548/beam-therapeutics-announces-positive-initial-data-for-beam-302-in-the-phase-12-trial-in-alpha-1-an" rel="noreferrer noopener">cut-off date</a>.
Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42393770/beam-therapeutics-unveils-new-safety-efficacy-data-from-sickle-cell-disease-candidate-stock-gains" rel="noreferrer noopener">Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains</a>
Alpha-1 antitrypsin (AAT) deficiency is&nbsp;a genetic disorder that can cause lung disease and liver disease.&nbsp;It occurs when the body doesn&#8217;t produce enough AAT, a protein that protects the lungs and liver.&nbsp;
Following a single infusion of BEAM-302, rapid, durable and dose-dependent increases in total AAT, a new production of corrected M-AAT and decreases in mutant Z-AAT were observed in circulation.
<ul>
<li>Changes in total AAT were observed as early as Day 7, plateaued around Day 21 and were maintained for the duration of follow-up (up to Month 6 in the 15 mg cohort, Month two in the 30 mg cohort and Day 28 in the 60 mg cohort).</li>
<li>Increased total AAT was functional.</li>
</ul>
Beam plans to continue the dose-escalation portion of Part A of the ongoing Phase 1/2 trial, including enrolling and dosing a fourth dose cohort. It also expects to report further data at a medical conference in the second half of 2025.
In addition, the company plans to dose the first patient in Part B, including AATD patients with mild to moderate liver disease, in the second half of 2025.
Concurrently, Beam Therapeutics priced the underwritten offering of 16.15 million shares at $28.48 per share and pre-funded warrants to purchase 1.4 million at $28.47 per pre-funded warrant, with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214581/beam-therapeutics-announces-pricing-of-underwritten-offering" rel="noreferrer noopener">approximately $500 million gross proceeds</a>.
Price Action: BEAM stock is down 3.44% at $27.50 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44217345/whats-going-on-with-palantir-stock-premarket-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Palantir Stock Premarket On Monday?</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Financing

Offerings

Movers

General

BEAM

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Barclays analyst Karen Short maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Equal-Weight and raises the price target from $940 to $980.

COST

Barclays Maintains Equal-Weight on Costco Wholesale, Raises Price Target to $980

ServiceNow's agentic AI and automation strengths plus Moveworks' front-end AI assistant and enterprise search technology to accelerate enterprise AI adoption and innovation
Together with Moveworks, ServiceNow will drive use of its agentic AI platform across key growth areas including CRM
ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), the AI platform for business transformation, today announced it has signed a definitive agreement to acquire Moveworks. The acquisition will combine ServiceNow's agentic AI and automation strengths with Moveworks' front-end AI assistant and enterprise search technology to unlock new experiences for every employee for every corner of the business. Following closing, together with Moveworks, ServiceNow – with thousands of AI agents already deployed – will continue to drive use of its agentic AI ServiceNow Platform to accelerate enterprise adoption and innovation across key growth areas including CRM.
&nbsp;
Transaction details
Under the terms of the agreement, ServiceNow will acquire Moveworks for $2.85 billion, subject to customary purchase price adjustments, payable in a combination of cash and stock. The transaction is expected to close in the second half of 2025, subject to customary regulatory approvals and closing conditions.

ServiceNow Has Signed A Definitive Agreement To Acquire Moveworks For $2.85B

Raymond James analyst John Davis upgrades Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) from Outperform to Strong Buy and announces $140 price target.

Upgrades

FOUR

Raymond James Upgrades Shift4 Payments to Strong Buy, Announces $140 Price Target

Barclays analyst Karen Short maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Equal-Weight and raises the price target from $80 to $115.

Barclays Maintains Equal-Weight on BJ's Wholesale Club, Raises Price Target to $115

Raymond James analyst Patrick O'Shaughnessy upgrades CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) from Market Perform to Outperform and announces $287 price target.

Raymond James Upgrades CME Group to Outperform, Announces $287 Price Target

Macro strategist Raoul Pal has shared his outlook for crypto investors amid recent market volatility, emphasizing that patience and proper risk management are essential for <a href="https://www.benzinga.com/money/bitcoin-price-prediction">surviving this correction</a>.
What Happened: In a <a href="https://www.youtube.com/watch?v=W7ZL-nFoynw">podcast</a> on March 1, Pal described the downturn as part of a normal bull market correction, driven by tightening global financial conditions. He explained that &#8220;Financial conditions tightened last year due to the dollar rallying in anticipation of Trump and rising rates ahead of potential tariffs.&#8221;
His core advice centers on risk management: &#8220;If you&#8217;re using leverage, you are going to get blown out and you&#8217;re going to lose control of your tokens.&#8221;
Pal referenced his M2 money supply model, developed with analyst Julian Batella, which has accurately predicted Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price movements with a 10-week lag. 
Addressing Solana's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) 53% decline, Pal dismissed concerns that the asset is failing. He called claims that Solana is a &#8220;scam coin&#8221; or &#8220;dead coin&#8221; nonsense, arguing that SOL remains a deep and robust protocol.
 He also pointed out that its price looks undervalued relative to global M2 trends.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44143660/howard-lutnick-says-president-definitely-thinks-theres-a-bitcoin-strategic-reserve">Howard Lutnick Says &#8216;President Definitely Thinks There&#8217;s A Bitcoin Strategic Reserve&#8217;</a>
What's Next: Despite short-term turbulence, Pal remains optimistic about the bigger picture.
He expects the market to recover by mid-March, calling the current phase the &#8220;healing stage&#8221; and predicts that April, May, and June will mark the second phase of the Banana Zone, ushering in significant bullish price action across the crypto space. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44174606/jpmorgan-questions-viability-of-us-crypto-reserve-cites-issues-with-smaller-tokens">JPMorgan Questions Viability of US Crypto Reserve, Cites Issues With Smaller Tokens</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$SOL

Raoul Pal Sees Bitcoin, Solana In 'Healing Stage', Predicts Market Recovery In Q2

Outlook
•First Quarter Guidance: Forecasts 7% to 15% sequential revenue growth, revenues of $28.2 million - $30.2 million, Adjusted EBITDA2 loss of $1.8 million to $0.8 million and positive cash flow
•Full Year: Forecasts significant improvements in revenue, adjusted EBITDA, and cash flow

Guidance

Telos Expects Q1 Revenue Of $28.2 M-$30.2M Vs $32.46M Est

Dividends

Safe And Green Development Declares Stock Dividend

Barclays analyst Matt Miksic maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Overweight and raises the price target from $39 to $41.

Barclays Maintains Overweight on Baxter Intl, Raises Price Target to $41

Arthur J. Gallagher & Co Acquires The Remaining Shares Of Philippines-Based Philpacific Insurance Brokers & Manager; Terms Not Disclosed

Keybanc analyst Jason Celino upgrades Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) from Sector Weight to Overweight and announces $245 price target.

PAYC

Keybanc Upgrades Paycom Software to Overweight, Announces $245 Price Target

CLSK

Reported March 7, 2025: CleanSpark Will Join S&P SmallCap 600, Effective Prior To The Open Of Trading On Monday, March 24, 2025

Smoker Friendly Adds Both VLN and Smoker Friendly Branded VLN Reduced Nicotine Content Products to its Store Lineup
MOCKSVILLE, N.C., March 10, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), a tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced that it has signed an agreement with Smoker Friendly, one of its largest customers, to launch Smoker Friendly VLN branded reduced nicotine content cigarette products that will become the first VLN partner brand.
The introduction of Smoker Friendly VLN and 22nd Century VLN in Smoker Friendly outlets will be one of the first presentations of gold and menthol SKU's that introduce the new VLN branding.

XXII

22nd Century Signs An Agreement With Smoker Friendly To Launch Smoker Friendly VLN Branded Reduced Nicotine Content Cigarette Products That Will Become The First VLN Partner Brand

Earnings Beats

Telos Q4 2024 Adj. EPS $(0.04) Beats $(0.09) Estimate, Sales $26.372M Beat $25.623M Estimate

Barclays analyst Brandt Montour maintains Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) with a Equal-Weight and lowers the price target from $18 to $14.

BALY

Barclays Maintains Equal-Weight on Ballys, Lowers Price Target to $14

Eligible shoppers can now pay over time for coveted sneakers, apparel, accessories and more with Affirm's customized biweekly and monthly payment plans
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fstockx.com%2F&amp;esheet=54221089&amp;newsitemid=20250310115375&amp;lan=en-US&amp;anchor=StockX&amp;index=1&amp;md5=afc7619100411b206c93b9c6e02f9861">StockX</a>, a global resale marketplace for current culture products, today announced that it has partnered with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affirm.com%2F&amp;esheet=54221089&amp;newsitemid=20250310115375&amp;lan=en-US&amp;anchor=Affirm&amp;index=2&amp;md5=fdcce344d968844000767a95850628c4">Affirm</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), the payment network that empowers consumers and helps merchants drive growth. Eligible StockX shoppers in the U.S. can now access Affirm's flexible payment plans when purchasing coveted items from top brands like adidas, Supreme, Gucci, and more.

AFRM

Affirm And StockX Partner To Offer New, Transparent Payment Offering

Buybacks

ELMD

Electromed Announces Its Board of Directors Authorizes The Repurchase Of Up To $5M Of Electromed Common Stock.

Oppenheimer analyst Scott Schneeberger maintains WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) with a Outperform and lowers the price target from $41 to $38.

Oppenheimer Maintains Outperform on WillScot Holdings, Lowers Price Target to $38

Press Releases

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

GeneDx to Participate in 45th Annual TD Cowen Health Care Conference

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp - WGS

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

BIIB

PRAX

STOK

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

GeneDx Holdings

Noticias

Últimas noticias sobre GeneDx Holdings (NASDAQ:WGS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL